By G HossainPosted on July 28, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total. Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch Post navigation Oak Hill takes SPAC track to Nasdaq with Roche asset in towGSK shares rise as $2.5B cost-cutting plan unveiled
